Psilocybin Pharmacology
>3× more brain disruption than Ritalin
A single psilocybin dose causes more than three times greater disruption of brain-wide connectivity than methylphenidate, and some of those changes persist for weeks after the session ends.
Siegel et al., Nature, 2024
60–70%
5-HT2A receptor occupancy at therapeutic doses (Madsen et al., 2019)
r=0.75
correlation: receptor occupancy vs. psychedelic experience intensity
+7.4%
increase in synaptic density one week after a single dose (Raval et al., 2021)
Siegel et al., Nature, 2024
View as image ↗The question sounds simple: how does psilocybin work? Decades of research have produced a surprisingly precise answer, built from pharmacokinetics, receptor imaging, brain scans, and cellular biology. Psilocybin is a compound found in certain mushrooms that the body converts into another molecule called psilocin, which then binds to a specific type of serotonin receptor in the brain, disrupting the normal synchronization of brain networks and triggering lasting structural changes at the level of individual neurons. None of those steps were understood simultaneously until recently. This guide walks through each one.
The short version, as a direct answer to the search: psilocybin is a prodrug. Your body converts it to psilocin via enzymes in the gut and liver. Psilocin acts as a partial agonist at serotonin 5-HT2A receptors, the type most densely concentrated in the outer cortex. At typical therapeutic doses of around 20–25 mg in an average adult, psilocin occupies 60–70% of available 5-HT2A receptors and causes widespread disruption of brain network synchrony. Effects begin 20–60 minutes after oral ingestion, peak around 90 minutes, and last roughly four to six hours. The lasting effects on mood and brain structure appear to come from a separate mechanism: psilocin also activates 5-HT2A receptors located inside neurons, specifically in a cellular compartment called the Golgi apparatus, where it triggers the growth of new synaptic connections. Serotonin itself cannot reach those receptors.
Key Takeaways
- Psilocybin is not itself active in the brain; the body converts it to psilocin via alkaline phosphatase enzymes, primarily in the gut and liver (Geiger et al., 2018)
- At therapeutic doses of around 0.2–0.3 mg/kg, psilocin occupies 60–70% of brain 5-HT2A receptors, and that occupancy directly predicts how intense the psychedelic experience will be (r=0.75, Madsen et al., 2019)
- Psilocybin causes more than 3x greater disruption of brain-wide connectivity than methylphenidate (Ritalin); some of that disruption, particularly involving the hippocampus, persists for three or more weeks (Siegel et al., Nature, 2024)
- A 2023 paper in Science found that psilocin activates 5-HT2A receptors located inside neurons in the Golgi apparatus, not just on the cell surface; serotonin cannot access these receptors because it cannot cross the cell membrane (Vargas et al., 2023)
- A single psilocybin dose increased synaptic density in pig prefrontal cortex by 7.4% at seven days, providing direct imaging evidence of new synapse formation (Raval et al., 2021)
- People with fewer 5-HT2A receptors at baseline tend to report more intense experiences under psilocybin, the counterintuitive opposite of what most would predict (Stenbæk et al., 2021)
How Psilocybin Becomes Active in the Body: The Prodrug Chemistry
The compound most people call "the psychedelic" in magic mushrooms is actually inactive in the brain. Psilocybin has a phosphate group attached to its tryptamine core. That group makes it water-soluble and chemically stable, which is useful, but it also prevents psilocybin from crossing cell membranes.
Geiger and colleagues published a comprehensive review of psilocybin chemistry in ACS Chemical Neuroscience in 2018, tracing the full metabolic pathway back to Albert Hofmann's original 1958 characterization of psilocybin and its active metabolite psilocin.[1] When psilocybin is swallowed, alkaline phosphatases and esterases in the gut wall and liver strip away the phosphate group via dephosphorylation. What remains is psilocin, a lipid-soluble molecule that crosses cell membranes freely, including the blood-brain barrier.
Psilocin is what does the work. Psilocybin is essentially a stable delivery vehicle: a storable, stable form of the active compound that the body converts on demand.
This distinction matters more than it first appears. The mushroom, too, benefits from this chemistry: psilocin is chemically unstable and degrades rapidly with heat and oxidation, while psilocybin remains chemically robust under the same conditions. The mushroom stores psilocybin, not psilocin, because psilocybin survives long enough to serve its biological purpose. Psilocin is produced when needed, in the body.
For a detailed comparison of the two molecules (molecular weight, receptor potency, half-life, and the evolutionary logic of storing the prodrug form), see our companion article on psilocybin vs. psilocin.
The Timeline: From First Dose to Peak Effects
Once converted, psilocin enters the bloodstream and then the brain. The timing is consistent enough to describe with precision.
Brown and colleagues published the first rigorous dose-escalation pharmacokinetics study in 2017, measuring psilocin blood levels in 12 healthy adults who received oral psilocybin at doses ranging from 0.5 to 3 mg/kg body weight.[2] Across that entire dose range, psilocin reached peak concentrations in blood at around 90 minutes after ingestion. The pharmacokinetics were dose-proportional: doubling the dose doubled the plasma exposure rather than producing disproportionate accumulation or toxicity. In pharmacological terms, that linear relationship is a sign of a relatively clean compound.
Holze and colleagues provided a finer-grained picture in 2023, using a tightly controlled design with 16 participants who each received 0.215 mg/kg oral psilocybin.[3] Psilocin peaked at about 1.5 hours, with an elimination half-life of 3.3 hours. Holze's team also measured subjective experience intensity at regular intervals, and the correlation between psilocin plasma concentration and how intense the experience felt was r=0.82. As the drug level rose, the experience intensified. As it cleared, the experience faded. The plasma level tracked the experience in near real-time.
A 2025 systematic review by Meshkat and colleagues, covering 25 pharmacokinetic studies across the literature, synthesized these findings: oral psilocybin consistently produced psilocin plasma peaks between 84 and 109 minutes, with elimination half-lives of 2.6–3.7 hours.[4] The review also flagged a consistent finding: individual variability is large. The coefficient of variation in plasma exposure at the same nominal dose is around 50%. Two people taking identical amounts of psilocybin can end up with meaningfully different blood levels; the review found that body weight alone is a poor predictor of that variability. Other factors are almost certainly involved, but what those factors are remains an open research question.
For a dedicated deep dive into absorption timing, the conversion process, and what drives individual differences, see psilocybin pharmacokinetics: onset, peak, and duration.
The Receptor That Matters: Why 5-HT2A Drives the Psychedelic Experience
Once psilocin reaches the brain, it binds to serotonin receptors, but not all serotonin receptor types equally. The receptor that drives the psychedelic experience is called 5-HT2A. This type is densely concentrated in the outer layers of the cortex, especially in the prefrontal cortex regions responsible for cognition, perception, and self-referential thinking.
Nichols published a landmark 91-page review in Pharmacological Reviews in 2016, establishing that serotonergic psychedelics like psilocin act as partial agonists at 5-HT2A receptors. They activate the receptor, but not as fully as the natural signal molecule serotonin would at that site.[5] Psilocin also has some affinity for 5-HT1A and 5-HT2C receptors, which appear to modulate aspects like temperature regulation and anxiety, but the 5-HT2A activation drives the core psychedelic response. Psilocybin, the inactive prodrug, has essentially no binding affinity at 5-HT2A at all, confirming that the prodrug itself does nothing at the receptor level.
The most direct human evidence for 5-HT2A as the causal mechanism came from a 2019 study by Madsen and colleagues at the University of Copenhagen.[6] Using PET brain imaging, a technique that measures how many receptors in the brain are occupied by a drug in real time, they gave nine participants psilocybin at therapeutic doses and simultaneously measured receptor occupancy and subjective experience intensity. Doses around 0.2–0.3 mg/kg achieved 60–70% occupation of available 5-HT2A receptors. That occupancy level correlated with how psychedelic the experience felt at r=0.75. This was the first quantified, direct evidence in humans that 5-HT2A binding drives the psychedelic response. The relationship was not perfect, suggesting individual factors other than receptor binding contribute, but the relationship was strong and causal.
One finding from this body of receptor research is counterintuitive. Stenbæk and colleagues measured 5-HT2A receptor density in 19 healthy adults before giving them psilocybin, then measured how intense the subsequent experience was.[7] People who started with fewer 5-HT2A receptors reported stronger mystical experiences under psilocybin. The opposite of what a simple "more receptors, more effect" model would predict. The mechanism behind this inverse relationship is not fully established, but it likely involves downstream signaling amplification: when the receptor population is smaller, each individual activation event may produce a proportionally larger signal in the neurons downstream.
For a detailed breakdown of psilocin's binding profile across all receptor types (including how it compares to serotonin, LSD, and the minor tryptamines found in mushrooms), see psilocybin receptor binding affinity: why 5-HT2A selectivity matters.
The 2023 Science Discovery: Why Serotonin Can't Do What Psilocybin Does
Here is the single most important mechanistic finding published in the last decade of psilocybin research, and it is almost entirely absent from popular writing on the topic.
In 2023, Vargas and colleagues published a paper in Science, the premier general-science journal, documenting a discovery that reframes the entire pharmacology of psychedelics.[8] Psilocin doesn't just activate 5-HT2A receptors on the outer surface of neurons. It also activates a population of 5-HT2A receptors located inside neurons, specifically in a cellular structure called the Golgi apparatus, and it is those interior receptors that trigger the growth of new dendritic spines. Dendritic spines are the structural connection points between neurons that encode learning and memory.
Serotonin cannot do this. Serotonin is water-soluble. It cannot cross the lipid membrane surrounding the neuron. It binds to receptors on the neuron's outer surface and no further. Psilocin is lipid-soluble. It crosses the membrane freely, gets inside the cell, and finds a whole population of 5-HT2A receptors in the Golgi apparatus that serotonin has never reached.
When psilocin activates those intracellular receptors, it sets off a chain of molecular events inside the neuron, involving signaling pathways known as mTOR and AMPA, that ultimately results in the physical growth of new dendritic spines. The neuron builds new connection points. This is a structural change, not a temporary electrical one.
This is why SSRIs don't produce the same effects as psilocybin. SSRIs increase the amount of serotonin available in the spaces between neurons, the synaptic cleft. They flood the cell's exterior environment with the natural signal molecule. But that serotonin never gets inside the cell to activate the receptor population that drives spine growth. Psilocin bypasses that limitation by being the right shape and lipid solubility to cross the membrane.
The implications are significant: this is a mechanistic explanation for why antidepressants and psychedelics produce qualitatively different effects despite both involving serotonin systems. And it reframes the question of what a psychedelic treatment is actually doing, not just modulating neurotransmission, but remodeling the physical architecture of synaptic connections.
For a complete analysis of this receptor mechanism and what happens downstream in the neuron, see psilocybin and the 5-HT2A receptor: the key to psychedelic effects.
What the First Brain Scans Found: The Pioneer Imaging Data
While receptor pharmacology explains the molecular level, a separate line of research used brain imaging to document what psilocybin does to entire neural networks.
Carhart-Harris and colleagues published the first neuroimaging study of psilocybin's effects in PNAS in 2012, scanning 15 volunteers under psilocybin and placebo using functional MRI, a technique that tracks brain blood flow as a proxy for neural activity.[9] The most striking finding was the opposite of what many expected: psilocybin decreased activity in specific brain regions rather than increasing it. The most affected areas were the medial prefrontal cortex and the posterior cingulate cortex, two core hubs of a network called the default mode network. The default mode network is most active when a person is thinking about themselves, ruminating, or mind-wandering. The psilocybin sessions quieted it.
The suppression of these self-referential hubs correlated with participants' descriptions of altered experience. The brain was not being flooded with random activity. Key self-referential circuits were going quiet.
In 2014, Carhart-Harris and colleagues proposed a theoretical framework for why disrupting this network might matter therapeutically.[10] The entropic brain hypothesis proposed that the brain normally operates under tight top-down constraints: prior beliefs and mental models that filter incoming information to maintain predictable, efficient processing. Psychedelics increase neural signal entropy, meaning the diversity and unpredictability of neural firing patterns, temporarily loosening those constraints. The framework, named REBUS (Relaxed Beliefs Under Psychedelics), suggests that in a high-entropy state, rigid thought patterns become more revisable. Depressive rumination loops, addiction-related habit structures, and anxiety cycles may be more susceptible to change during a window of temporarily increased brain flexibility. For a full analysis of the entropy model and the evidence behind it, see how psilocybin increases brain entropy and why that matters.
Nature, 2024: The Most Quantitative Brain Imaging Data Yet
The 2012 Carhart-Harris paper established the phenomenon but worked with small samples and the tools of that era. By 2024, the methodology had advanced, and Siegel and colleagues published what is now the most comprehensive quantification of psilocybin's brain-network effects in the journal Nature.[11]
Siegel scanned seven participants (a small sample, but with high-resolution imaging and a carefully chosen active comparator) under both psilocybin and methylphenidate (Ritalin). Methylphenidate was chosen because it is pharmacologically active and psychologically stimulating, providing a meaningful baseline against which psilocybin's effects could be measured. The difference between the two was not subtle. Psilocybin caused more than three times greater disruption of brain-wide functional connectivity than methylphenidate. The effect was not limited to the default mode network. Synchronized activity was disrupted across all major brain networks simultaneously.
The magnitude of that disruption correlated with subjective experience intensity at r=0.64: participants who showed more widespread brain desynchronization reported more intense experiences. And not all the changes resolved quickly. The coupling between the hippocampus and the default mode network, which normally keeps memory-processing systems coordinated with self-referential networks, had not fully returned to baseline in scans taken three or more weeks after the session.
The Siegel 2024 data represents the most quantified modern picture of psilocybin's acute effects: broad, synchronized disruption, larger in magnitude than any comparator substance tested to date, correlating in real time with what participants report, and producing some connectivity changes that outlast the pharmacokinetic window by weeks.
For a time-based account of what these brain changes look like at each stage (during the session, one week later, and one month out), see what happens in your brain on psilocybin: a neuroscience explainer.
Lasting Changes: Why a Single Session Can Rewire the Brain
The question most people actually want answered is not what happens during the experience but what stays different afterward. Three lines of research converge on a cellular answer.
First, Raval and colleagues used SV2A-PET imaging, the same technique used to count overall synapse density in human brain studies, to scan pig brains before and after a single psilocybin dose.[12] Seven days after the dose, synaptic density in the prefrontal cortex had increased by 7.4%. At the same time, 5-HT2A receptor density had decreased by 4.4%, a receptor downregulation response consistent with sustained activation. This was the first direct imaging evidence of new synapse formation following psilocybin. The SV2A-PET methodology is the same one used in human brain studies, making the pig data more translatable than typical rodent experiments.
Second, Zhao and colleagues demonstrated in 2024 that psilocybin's neuroplasticity effects in mice (measured as increased dendritic spine density in the prefrontal cortex and reduced depressive-like behavior sustained for 14 days) were completely abolished when researchers blocked AMPA receptors.[13] This confirmed that the intracellular 5-HT2A pathway identified by Vargas 2023 operates through downstream AMPA signaling. The structural changes are not a secondary consequence of the experience itself; they depend on a specific molecular mechanism that can be interrupted pharmacologically.
Third, Shao and colleagues used genetic tools in mouse models to selectively remove 5-HT2A receptors from specific neuron types (this work was published as a preprint in 2024 and has not yet completed peer review).[14] When 5-HT2A was removed specifically from layer-5 pyramidal neurons in the prefrontal cortex, neurons that project widely across the brain, both the acute psychedelic response and the lasting spine density increases were eliminated. The critical cell type appears to be these layer-5 neurons at a specific depth in the cortex.
The mechanistic picture these three studies support is coherent: psilocin crosses the cell membrane, finds 5-HT2A receptors inside layer-5 pyramidal neurons in the Golgi apparatus, activates an AMPA-dependent plasticity cascade, and new synaptic connections form over the following days. The widespread brain desynchronization documented by Siegel 2024 may create the temporal window during which that structural rewiring is consolidated; the synapse growth itself appears to be a direct pharmacological effect, not a downstream consequence of the experience.
The Supporting Cast: Minor Tryptamines and a Future Without Hallucinations
Natural psilocybin mushrooms contain more than just psilocybin. Sherwood and colleagues evaluated the pharmacology of four minor tryptamines found in hallucinogenic mushrooms: baeocystin, norbaeocystin, norpsilocin, and aeruginascin.[15] Baeocystin showed similar 5-HT2A binding affinity to psilocin in cell-based assays, though its potency in animal models was lower. Norbaeocystin was weakly active. Aeruginascin, however, acted as a 5-HT3 antagonist, a completely different receptor type, rather than a 5-HT2A agonist. The 5-HT3 receptor plays a role in nausea signaling, which has led researchers to speculate that aeruginascin might modulate nausea during mushroom experiences, though this has not been demonstrated in humans. Whether any of these minor compounds contribute meaningfully to the whole-mushroom experience remains an open question.
At the research and development level, the pharmacology of 5-HT2A signaling has raised a question: can the neuroplasticity effects be separated from the psychedelic experience? McClure-Begley and Roth reviewed this in Nature Reviews Drug Discovery in 2022, outlining the concept of biased agonism.[16] The 5-HT2A receptor can signal through at least two distinct intracellular routes when activated: through a protein called Gq and through a protein called beta-arrestin 2. Current evidence suggests the hallucinogenic effects depend primarily on one pathway, and the plasticity effects on the other. In theory, a compound could be engineered to preferentially activate the plasticity pathway while leaving the hallucinogenic pathway largely unstimulated. These compounds are called psychoplastogens. None has reached human clinical trials yet, but the pharmacological logic is grounded in the same receptor biology that underlies psilocybin's effects.
The 5-HT2A receptor downregulation documented by Raval 2021, a 4.4% reduction in receptor density at seven days post-dose, also explains the rapid tolerance development that anyone who has used psilocybin repeatedly has observed. The receptor adapts quickly to sustained activation. For a detailed look at how this tolerance develops and how quickly it resolves, see psilocybin tolerance: how fast does it build?.
What the Evidence Has and Hasn't Established
Psilocybin's mechanism is better characterized than it was a decade ago, but several important gaps remain.
The Siegel 2024 Nature paper involved seven participants. The quantitative data is compelling and the active comparator design is rigorous, but the sample is small. The ">3x methylphenidate" figure represents the best current estimate with a real comparator, not a definitively settled number. Replication in larger cohorts is needed before that figure should be treated as exact.
The Vargas 2023 intracellular receptor discovery was demonstrated primarily in cell culture systems and rodent models, not in living human brains. The techniques for imaging intracellular receptor activation in a living person do not yet exist. The finding is scientifically credible and methodologically rigorous, but its direct applicability to human pharmacology at therapeutic doses is still being established.
The Shao 2024 work on layer-5 pyramidal neurons has not yet completed peer review. It is presented here as emerging research, not established fact.
The large individual variability documented across pharmacokinetic studies, around 50% coefficient of variation in plasma exposure, means population-level findings describe averages that may not describe any particular person well. What drives those individual differences in bioavailability and brain response is not yet understood.
The Bottom Line
Psilocybin works through a sequence of biological events: conversion to psilocin in the gut and liver, binding at 5-HT2A receptors in the cortex, broad disruption of brain network synchrony during the session, and activation of intracellular 5-HT2A receptors that trigger lasting synaptic growth. Each step has been documented with specific data, and the evidence points to a mechanistically coherent account of both the acute experience and the lasting effects. The individual variability is substantial and poorly understood; the same dose produces different plasma levels, different receptor occupancy, and different experiences in different people. Several key findings from 2023 and 2024 are still being replicated and extended. The broad outline is well supported; the fine details are not.
Frequently Asked Questions
Sources & References
- 1. Source details for this reference are not yet available.
- 2. Source details for this reference are not yet available.
- 3. Source details for this reference are not yet available.
- 4. Source details for this reference are not yet available.
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.
- 8. Source details for this reference are not yet available.
- 9. Source details for this reference are not yet available.
- 10. Source details for this reference are not yet available.
- 11. Source details for this reference are not yet available.
- 12. Source details for this reference are not yet available.
- 13. Source details for this reference are not yet available.
- 14. Source details for this reference are not yet available.
- 15. Source details for this reference are not yet available.
- 16. Source details for this reference are not yet available.